Oliveira Lilian Caroline Gonçalves, Cruz Nayara Azinheira Nobrega, Ricelli Bruna, Tedesco-Silva Helio, Medina-Pestana José Osmar, Casarini Dulce Elena
Nephrology Division, Department of Medicine, Universidade Federal de São Paulo (UNIFESP/EPM), São Paulo, SP, Brazil.
J Venom Anim Toxins Incl Trop Dis. 2021 Dec 6;27:e20200181. doi: 10.1590/1678-9199-JVATITD-2020-0181. eCollection 2021.
Coronavirus disease 2019 (COVID-19) is a rapid-spread infectious disease caused by the SARS-CoV-2 virus, which can culminate in the renin-angiotensin-aldosterone (RAAS) and kallikrein-kinin (KKS) systems imbalance, and in serious consequences for infected patients. This scoping review of published research exploring the RAAS and KKS was undertaken in order to trace the history of the discovery of both systems and their multiple interactions, discuss some aspects of the viral-cell interaction, including inflammation and the system imbalance triggered by SARS-CoV-2 infection, and their consequent disorders. Furthermore, we correlate the effects of continued use of the RAAS blockers in chronic diseases therapies with the virulence and physiopathology of COVID-19. We also approach the RAAS and KKS-related proposed potential therapies for treatment of COVID-19. In this way, we reinforce the importance of exploring both systems and the application of their components or their blockers in the treatment of coronavirus disease.
2019冠状病毒病(COVID-19)是一种由严重急性呼吸综合征冠状病毒2(SARS-CoV-2)引起的快速传播的传染病,它可能导致肾素-血管紧张素-醛固酮系统(RAAS)和激肽释放酶-激肽系统(KKS)失衡,并给感染患者带来严重后果。本综述对已发表的关于RAAS和KKS的研究进行了概述,以追溯这两个系统的发现历史及其多种相互作用,讨论病毒与细胞相互作用的一些方面,包括炎症以及由SARS-CoV-2感染引发的系统失衡及其随之而来的紊乱。此外,我们将在慢性疾病治疗中持续使用RAAS阻滞剂的效果与COVID-19的毒力和病理生理学联系起来。我们还探讨了与RAAS和KKS相关的、针对COVID-19的潜在治疗方法。通过这种方式,我们强化了探索这两个系统以及在冠状病毒病治疗中应用其组成部分或阻滞剂的重要性。